Company intelligence / Profile preview

Extrawell Pharmaceutical

Changchun, Jilin, Chinaextrawell.com.hk ↗

Ownership: Private
Employees: ~159
Development stage: Commercial

Overview

Extrawell Pharmaceutical develops, manufactures, markets, and distributes a range of pharmaceutical products in China and Hong Kong. Its portfolio includes marketed drugs such as transfer factor oral solution for immune regulation and Wisk for skin injuries. The company is also developing an oral insulin product currently in clinical trials with commercialization expected around Q1 2026. Clinical progress was delayed by COVID-related disruptions but has resumed.

Therapeutic areas: DermatologyCardiovascularEndocrinologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

1 asset

Transfer Factor Oral Solution

Unknown

Partnerships

not explicitly listed; works with business partners to develop new lines of imported pharmaceuticals

Beyond the preview

Go deeper on Extrawell Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Extrawell Pharmaceutical.

Explore the full profile